Corbus Pharmaceuticals Holdings, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $8.26 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2018-05-10
- Corbus Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was $8.26M, a 75.66% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was $33.93M.
- Corbus Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $47.50M, a 1585.98% increase from fiscal 2016.
- Corbus Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2016 was $2.82M, a 53.80% decline from fiscal 2015.
- Corbus Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2015 was $6.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2018-03-31 | $8.26M 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $47.50M 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $21.61M 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $28.04M 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $33.93M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $2.82M 10-K · filed 2018-03-12 | |||
| 2016-09-30 | $6.72M 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | $9.69M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $6.10M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |